Download PDF

Sanjeev Krishna is a Section Editor for BMC Infectious Diseases, a journal dedicated to research on all aspects of the prevention, diagnosis and management of infectious and sexually transmitted diseases in humans.

As a professor of molecular parasitology and medicine at St George’s, University of London, UK, and a consultant physician in infectious diseases, Krishna’s research interests centre around one of the most lethal vector borne diseases – malaria. His work particularly focuses on antimalarial function and resistance, and the identification of new drugs and drug targets. We spoke to Krishna about antimalarial resistance, as well as what the future may hold in terms of the global burden of infectious disease and new therapeutic strategies to combat this.


“We’ll still get infections that we are used to seeing now being a problem in the future. The difficulty with them will be that a lot of them will have become resistant one way or another. Whether its gonorrhoea or Clostridium difficile or malaria.”
Sanjeev Krishna, St George’s, University of London


Krishna read Natural Sciences at the University of Cambridge, UK, and completed his medical degree at the University of Oxford, UK. His interest in malaria began as a medical student, with his involvement in clinical trials at the Wellcome Trust Unit in Thailand. Krishna continued to pursue research into treating malaria during his DPhil studies at the Weatherall Institute of Molecular Medicine, UK, and subsequent Wellcome Trust Senior Clinical Fellowship at St. George’s, University of London, UK.


“There are genuinely new classes of antimalarial that have got quite far down the line of clinical assessment. And to see some of these new classes being taken out to field studies, I think is very exciting.”
Sanjeev Krishna, St George’s, University of London


When it comes to disseminating the latest research findings, whether in the field of malaria research or other infectious diseases, Krishna notes the importance of Open Access: “When it comes to infectious diseases there may be an added importance because its often the disadvantaged who are affected by infections. And so those people who are working in areas that are disadvantaged may benefit disproportionately from Open Access.”

Related posts